Baxter International Faces Class Action Over Novum LVP Safety Concerns
- Baxter International is facing a class action lawsuit over safety concerns related to its Novum LVP intravenous fluid delivery product.
- Allegations claim Baxter knowingly misrepresented the Novum LVP's safety, leading to patient risks and potential injuries.
- Shareholders are urged to join the lawsuit by December 15, 2025, to recover losses from Baxter's alleged deceptive practices.
Baxter International Faces Class Action Lawsuit Over Novum LVP Product Issues
Baxter International, Inc. (NYSE: BAX) is currently embroiled in a class action lawsuit that raises serious concerns about the safety and efficacy of its Novum LVP product, a device used for intravenous fluid delivery. The Gross Law Firm has issued a notice inviting shareholders who purchased shares between February 23, 2022, and July 30, 2025, to join the lawsuit, which alleges that Baxter knowingly made materially false statements regarding the Novum LVP. Reports indicate that the product suffers from systemic defects leading to malfunctions such as underinfusion and overinfusion of fluids, which pose significant risks to patient safety. The lawsuit contends that Baxter was aware of multiple incidents where the device malfunctioned, resulting in injuries and even fatalities, yet failed to adequately address these concerns.
The allegations suggest that Baxter's attempts to communicate safety issues, such as through customer alerts, were insufficient. This negligence not only raises ethical questions about the company’s commitment to patient safety but also has serious implications for its business operations. Shareholders are particularly concerned about the potential withdrawal of existing Novum LVPs from service and the likelihood of halting new sales. This situation undermines Baxter’s previous assurances regarding the product's safety and efficacy, which has led to heightened scrutiny from investors and regulatory bodies alike.
As the lawsuit unfolds, Baxter faces the possibility of significant reputational damage and financial repercussions. The Gross Law Firm emphasizes that shareholders should act quickly to register for the class action, which is set to provide updates through a portfolio monitoring service. With a deadline of December 15, 2025, for registration, affected shareholders have the opportunity to recover losses attributed to Baxter’s alleged deceptive practices. The focus on the Novum LVP product highlights broader issues within the medical device industry, where patient safety and corporate accountability remain paramount.
In related news, Dr. Walter Jacobson, a psychiatrist and filmmaker, has gained attention with his comedy "Baxter's Brain," which secured 3rd place at the 2025 American Film Market Pitch Conference. The film critiques the medical field and is inspired by classic comedies, reflecting a unique intersection of healthcare and entertainment.
Related Cashu News

Merit Medical Systems Launches Employee Stock Ownership Plan to Boost Engagement and Stability
Merit Medical Systems (Ticker: MMSI) recently takes a significant step in enhancing its employee engagement and ownership structure with the launch of a new Employee Stock Ownership Plan (ESOP). The c…

Brookdale Senior Living launches second season of educational podcast "The Grey Take.
Brookdale Senior Living (Ticker: BKD) launches the second season of its popular podcast, "The Grey Take," which serves as a valuable resource for families exploring senior living options. The podcast…

Molina Healthcare Gains Momentum with Increased Risk Adjustment Payments and Positive Revenue Outlook
Molina Healthcare (Ticker: MOH) is making significant strides in its revenue outlook due to recently released risk adjustment figures from the Centers for Medicare & Medicaid Services (CMS). These upd…

Align Technology Faces Antitrust Investigation by European Commission Over Competitive Practices
Align Technology Inc. (Ticker: ALGN) faces a formal antitrust investigation from the European Commission, marking a significant development in the medical devices sector. This inquiry arises from a co…

